MoFo News Item

MoFo Advises Fiagon AG in Acquisition by Intersect ENT, Inc.

15 Sep 2020

Morrison & Foerster is advising the shareholders of Fiagon AG Medical Technologies, a leader in electromagnetic surgical navigation solutions, as sellers in the company’s €60 million cash acquisition by Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose, and throat (“ENT”) conditions.

Over the past 10 years, Fiagon, along with world-renowned physicians, changed the standard of ENT navigation with its easy-to-use electromagnetic-based technology. This unique technology is also currently used in oral and maxillofacial surgery, neurosurgery, and spine surgery outside of the U.S., mainly in Europe and Asia.

Under the terms of the transaction, Intersect ENT will make an initial €15 million payment at the time of the closing and €15 million annual payments for the subsequent three years. The transaction was announced on September 15, 2020 and is subject to customary closing conditions.

The MoFo deal team advising the shareholders of Fiagon is led by Berlin managing partner and head of the firm’s European Corporate and M&A groups Dirk Besse, together with Berlin partners Wolfgang Schoenig (Technology Transactions/Intellectual Property), Jens-Uwe Hinder (Tax), Hanno Timner (Employment/Labor), and Angela Kerek (Finance).

Read more about the transaction in Fiagon’s press release.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.